Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Drugs Made In America Acquisition Corp. ( (DMAA) ) is now available.
On October 8, 2025, Glenn Worman resigned as Chief Financial Officer of Drugs Made In America Acquisition Corp., effective immediately, citing no disagreements with the company. On November 17, 2025, Saleem Elmasri was appointed as the new CFO, with his services provided through a consulting agreement with Titan Advisory Services LLC. Mr. Elmasri brings 20 years of financial and management consulting experience, having previously worked with PwC and other advisory firms, and is expected to enhance the company’s financial operations.
More about Drugs Made In America Acquisition Corp.
Average Trading Volume: 39,966
Technical Sentiment Signal: Strong Buy
See more insights into DMAA stock on TipRanks’ Stock Analysis page.